Ehlers Justis P, Uchida Atsuro, Hu Ming, Figueiredo Natalia, Kaiser Peter K, Heier Jeffrey S, Brown David M, Boyer David S, Do Diana V, Gibson Andrea, Saroj Namrata, Srivastava Sunil K
The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Ophthalmol Retina. 2019 Dec;3(12):1056-1066. doi: 10.1016/j.oret.2019.06.010. Epub 2019 Jul 6.
To investigate retinal fluid features and ellipsoid zone (EZ) integrity dynamics on spectral-domain OCT (SD-OCT) in eyes with diabetic macular edema (DME) treated with intravitreal aflibercept injection (IAI) in the VISTA-DME study.
A post hoc subanalysis of a phase III, prospective clinical trial.
Eyes received either IAI 2 mg every 4 weeks (2q4) or every 8 weeks after 5 initial monthly doses (2q8).
All eyes from the VISTA Phase III study in the IAI groups imaged with the Cirrus HD-OCT system (Zeiss, Oberkochen, Germany) were included. The OCT macular cube datasets were evaluated using a novel software platform to generate retinal layer and fluid boundary lines that were manually corrected for assessment of change in EZ parameters and volumetric fluid parameters from baseline. The retinal fluid index (i.e., proportion of the retinal volume consisting of cystic fluid) was also calculated at each time point.
The feasibility of volumetric assessment of higher-order OCT-based retinal parameters and its correlation with best-corrected visual acuity (BCVA).
Overall, 106 eyes of 106 patients were included. Specifically, 52 eyes of 52 patients were included in the IAI 2q4 arm, and 54 eyes of 54 patients were included in the IAI 2q8 arm. Ellipsoid zone integrity metrics significantly improved from baseline to week 100, including central macular mean EZ to retinal pigment epithelium (RPE) thickness (2q4: 26.6 μm to 31.6 μm, P < 0.001; 2q8: 25.2 μm to 31.4 μm, P < 0.001). At week 100, central macular intraretinal fluid volume was reduced by >65% (P < 0.001) and central macular subretinal fluid volume was reduced by >99% in both arms (P < 0.001). Central macular retinal fluid index (RFI) significantly improved in both arms (2q4: 17.9% to 7.2%, P < 0.001; 2q8: 19.8% to 4.2%, P < 0.001). Central macular mean EZ-RPE thickness (i.e., a surrogate for photoreceptor outer segment length) and central RFI were independently correlated with BCVA at multiple follow-up visits.
Intravitreal aflibercept injection resulted in significant improvement in EZ integrity and quantitative fluid metrics in both 2q4 and 2q8 arms and correlated with visual function.
在VISTA-DME研究中,研究接受玻璃体内注射阿柏西普(IAI)治疗的糖尿病性黄斑水肿(DME)患者眼睛的视网膜液体特征和椭圆体带(EZ)完整性动态变化。
一项III期前瞻性临床试验的事后亚分析。
眼睛接受每4周注射2 mg阿柏西普(2q4)或在最初5次每月注射剂量后每8周注射一次(2q8)。
纳入VISTA III期研究中IAI组所有使用Cirrus HD-OCT系统(德国蔡司公司,奥伯科亨)成像的眼睛。使用一个新型软件平台评估OCT黄斑立方数据集,以生成视网膜层和液体边界线,并对其进行手动校正,以评估EZ参数和体积液体参数相对于基线的变化。还在每个时间点计算视网膜液体指数(即由囊性液体组成的视网膜体积比例)。
基于OCT的高阶视网膜参数进行体积评估的可行性及其与最佳矫正视力(BCVA)的相关性。
总体而言,纳入了106例患者的106只眼睛。具体而言,IAI 2q4组纳入了52例患者的52只眼睛,IAI 2q8组纳入了54例患者的54只眼睛。从基线到第100周,椭圆体带完整性指标显著改善,包括黄斑中心平均EZ到视网膜色素上皮(RPE)厚度(2q4:从26.6μm到31.6μm,P<0.001;2q8:从25.2μm到31.4μm,P<0.001)。在第100周时,两个治疗组的黄斑中心视网膜内液体体积均减少>65%(P<0.001),黄斑中心视网膜下液体体积均减少>99%(P<0.001)。两个治疗组的黄斑中心视网膜液体指数(RFI)均显著改善(2q4:从17.9%到7.2%,P<0.001;2q8:从19.8%到4.2%,P<0.001)。在多次随访中,黄斑中心平均EZ-RPE厚度(即光感受器外段长度的替代指标)和中心RFI与BCVA独立相关。
玻璃体内注射阿柏西普使2q4和2q8治疗组的EZ完整性和定量液体指标均显著改善,并与视觉功能相关。